TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Cost-effectiveness of Physiotherapy for Chronic Rotator Cuff Pathology
Brief Summary: The purpose of this study is to investigate whether a physiotherapy program reduces pain and improves disability and quality-of-life in people with chronic shoulder pain.

The main study hypotheses are that (i) A 10-week physiotherapy treatment will result in significantly greater reductions in pain and disability than placebo treatment in individuals with chronic shoulder pain (ii) Improvements in pain and disability following a 10-week physiotherapy treatment will be maintained at a 3-month follow-up.


Options:
A: Arm Label: PT progressive exercises; Type: EXPERIMENTAL; Interventions: Procedure: Exercise program | Arm Label: Movement exercises neck and shoulder; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Exercise program, Procedure: Movement exercises | Intervention Type: PROCEDURE; Name: Exercise program; Assigned to Arm(s): Movement exercises neck and shoulder, PT progressive exercises | Intervention Type: PROCEDURE; Name: Movement exercises; Assigned to Arm(s): Movement exercises neck and shoulder
B: Arm Label: Active physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Physiotherapy program | Arm Label: Placebo physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo physiotherapy treatment | Intervention Type: PROCEDURE; Name: Physiotherapy program; Assigned to Arm(s): Active physiotherapy | Intervention Type: PROCEDURE; Name: Placebo physiotherapy treatment; Assigned to Arm(s): Placebo physiotherapy
C: Arm Label: Barbotage; Type: EXPERIMENTAL; Interventions: Procedure: Barbotage | Arm Label: Corticosteroid injection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Corticosteroid injection | Arm Label: Lidocain injection (sham); Type: SHAM_COMPARATOR; Interventions: Procedure: Lidocain injection (sham) | Intervention Type: PROCEDURE; Name: Barbotage; Assigned to Arm(s): Barbotage | Intervention Type: PROCEDURE; Name: Corticosteroid injection; Assigned to Arm(s): Corticosteroid injection | Intervention Type: PROCEDURE; Name: Lidocain injection (sham); Assigned to Arm(s): Lidocain injection (sham)
D: Arm Label: Arthroscopic Sub-acromial Decompression; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic Sub-acromial Decompression Surgery | Arm Label: Shoulder Arthroscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Shoulder Arthroscopy | Arm Label: Active Monitoring with Specialist Reassessment; Type: OTHER; Interventions: Other: Active Monitoring with Specialist Reassessment | Intervention Type: PROCEDURE; Name: Arthroscopic Sub-acromial Decompression Surgery; Assigned to Arm(s): Arthroscopic Sub-acromial Decompression | Intervention Type: PROCEDURE; Name: Shoulder Arthroscopy; Assigned to Arm(s): Shoulder Arthroscopy | Intervention Type: OTHER; Name: Active Monitoring with Specialist Reassessment; Assigned to Arm(s): Active Monitoring with Specialist Reassessment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
Brief Summary: This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label, 52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia Purpura (ITP), with a 6-month Safety Follow-up. Patients randomized to romiplostim must complete the taper or discontinuation of medical SOC for ITP as soon as medically feasible after the initiation of romiplostim. After the completion or discontinuation of the study treatment period, any participant who does not transfer in to another romiplostim study will complete a 6-month Safety Follow-up period.


Options:
A: Arm Label: Romiplostim; Type: EXPERIMENTAL; Interventions: Biological: Romiplostim | Arm Label: Standard of Care; Type: OTHER; Interventions: Drug: Medical Standard of Care for ITP | Intervention Type: DRUG; Name: Medical Standard of Care for ITP; Assigned to Arm(s): Standard of Care | Intervention Type: BIOLOGICAL; Name: Romiplostim; Assigned to Arm(s): Romiplostim
B: Intervention Type: DRUG; Name: SB497115; Assigned to Arm(s): N/A
C: Arm Label: Romiplostim; Type: EXPERIMENTAL; Interventions: Biological: Romiplostim | Intervention Type: BIOLOGICAL; Name: Romiplostim; Assigned to Arm(s): Romiplostim
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: AMG 531; Type: EXPERIMENTAL; Interventions: Biological: AMG 531 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: AMG 531; Assigned to Arm(s): AMG 531

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Objective: To evaluate PCT as a marker of bacterial community acquired pneumonia in a Danish Hospital setting. To test if it is possible to reduce the use of antibiotics and the length of stay in hospital, and the willingness of the clinicians to take this new marker under advisement in their choice of treatment.

The study is a randomised, controlled intervention study. All adult patients admitted to the Department of Infectious Disease at Skejby hospital suspected of a lower respiratory tract infection (e.g. CAP, acute exacerbation of COPD and bronchitis) are eligible for inclusion. Patients are randomised to have either PCT guided treatment or standard care, in which case the doctor will not learn the PCT test result. In the PCT group the antibiotic treatment will be based on serum PCT as follows: If PCT is less than 0.25 µg/L antibiotic treatment is discouraged; if PCT is greater than 0.25 µg/L antibiotic treatment is encouraged and if PCT is greater than 0.5 µg/L antibiotic treatment is strongly encouraged. The treating doctor is allowed to overrule the treatment guidelines. The control group will receive antibiotics according to usual practice.

The primary endpoints are antibiotic use and length of stay in hospital. Secondary endpoint is the proportion of patients where the treating doctor chooses to disregard the guidelines.


Options:
A: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A
B: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A
C: Arm Label: DECISION+ Program; Type: EXPERIMENTAL; Interventions: Behavioral: Decision+ program (to improve optimal drug prescription for ARI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision+ program (to improve optimal drug prescription for ARI); Assigned to Arm(s): DECISION+ Program
D: Intervention Type: DRUG; Name: Macrolides (azithromycin or clarithromycin); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Objective: To evaluate PCT as a marker of bacterial community acquired pneumonia in a Danish Hospital setting. To test if it is possible to reduce the use of antibiotics and the length of stay in hospital, and the willingness of the clinicians to take this new marker under advisement in their choice of treatment.

The study is a randomised, controlled intervention study. All adult patients admitted to the Department of Infectious Disease at Skejby hospital suspected of a lower respiratory tract infection (e.g. CAP, acute exacerbation of COPD and bronchitis) are eligible for inclusion. Patients are randomised to have either PCT guided treatment or standard care, in which case the doctor will not learn the PCT test result. In the PCT group the antibiotic treatment will be based on serum PCT as follows: If PCT is less than 0.25 µg/L antibiotic treatment is discouraged; if PCT is greater than 0.25 µg/L antibiotic treatment is encouraged and if PCT is greater than 0.5 µg/L antibiotic treatment is strongly encouraged. The treating doctor is allowed to overrule the treatment guidelines. The control group will receive antibiotics according to usual practice.

The primary endpoints are antibiotic use and length of stay in hospital. Secondary endpoint is the proportion of patients where the treating doctor chooses to disregard the guidelines.


Options:
A: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A
B: N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
D: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Objective: To evaluate PCT as a marker of bacterial community acquired pneumonia in a Danish Hospital setting. To test if it is possible to reduce the use of antibiotics and the length of stay in hospital, and the willingness of the clinicians to take this new marker under advisement in their choice of treatment.

The study is a randomised, controlled intervention study. All adult patients admitted to the Department of Infectious Disease at Skejby hospital suspected of a lower respiratory tract infection (e.g. CAP, acute exacerbation of COPD and bronchitis) are eligible for inclusion. Patients are randomised to have either PCT guided treatment or standard care, in which case the doctor will not learn the PCT test result. In the PCT group the antibiotic treatment will be based on serum PCT as follows: If PCT is less than 0.25 µg/L antibiotic treatment is discouraged; if PCT is greater than 0.25 µg/L antibiotic treatment is encouraged and if PCT is greater than 0.5 µg/L antibiotic treatment is strongly encouraged. The treating doctor is allowed to overrule the treatment guidelines. The control group will receive antibiotics according to usual practice.

The primary endpoints are antibiotic use and length of stay in hospital. Secondary endpoint is the proportion of patients where the treating doctor chooses to disregard the guidelines.


Options:
A: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy
B: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
D: Arm Label: procalcitonin-guidance; Type: ACTIVE_COMPARATOR; Interventions: Other: procalcitonin-guidance | Arm Label: standard-of-care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: procalcitonin-guidance; Assigned to Arm(s): procalcitonin-guidance

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Objective: To evaluate PCT as a marker of bacterial community acquired pneumonia in a Danish Hospital setting. To test if it is possible to reduce the use of antibiotics and the length of stay in hospital, and the willingness of the clinicians to take this new marker under advisement in their choice of treatment.

The study is a randomised, controlled intervention study. All adult patients admitted to the Department of Infectious Disease at Skejby hospital suspected of a lower respiratory tract infection (e.g. CAP, acute exacerbation of COPD and bronchitis) are eligible for inclusion. Patients are randomised to have either PCT guided treatment or standard care, in which case the doctor will not learn the PCT test result. In the PCT group the antibiotic treatment will be based on serum PCT as follows: If PCT is less than 0.25 µg/L antibiotic treatment is discouraged; if PCT is greater than 0.25 µg/L antibiotic treatment is encouraged and if PCT is greater than 0.5 µg/L antibiotic treatment is strongly encouraged. The treating doctor is allowed to overrule the treatment guidelines. The control group will receive antibiotics according to usual practice.

The primary endpoints are antibiotic use and length of stay in hospital. Secondary endpoint is the proportion of patients where the treating doctor chooses to disregard the guidelines.


Options:
A: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
B: Arm Label: Lab-score group; Type: EXPERIMENTAL; Interventions: Biological: Allocation to the Lab-score group | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allocation to the control group | Intervention Type: BIOLOGICAL; Name: Allocation to the Lab-score group; Assigned to Arm(s): Lab-score group | Intervention Type: BIOLOGICAL; Name: Allocation to the control group; Assigned to Arm(s): Control group
C: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A
D: Arm Label: A; Type: NO_INTERVENTION; Interventions: Behavioral: Academic Detailing by the Antimicrobial Utilization Team (AUT) | Intervention Type: BEHAVIORAL; Name: Academic Detailing by the Antimicrobial Utilization Team (AUT); Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ecological Momentary Intervention of Diet Via Mobile Technology
Brief Summary: This is a NCI funded study which will develop and evaluate a cell phone application (mDIET) that can be used as an assessment and intervention tool to improve dietary behaviors and thus reduce weight in overweight and moderately obese (BMI 25-34.9) men and women ages 25-55.


Options:
A: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
C: Arm Label: PACE; Type: EXPERIMENTAL; Interventions: Behavioral: Printed Material, Behavioral: Weekly Weighing, Behavioral: Cell phone will serve as a self monitoring device, Device: Text Message, Behavioral: Diet Goals via Cell Phone, Behavioral: Food Monitoring | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Printed Material; Assigned to Arm(s): PACE | Intervention Type: BEHAVIORAL; Name: Weekly Weighing; Assigned to Arm(s): PACE | Intervention Type: BEHAVIORAL; Name: Cell phone will serve as a self monitoring device; Assigned to Arm(s): PACE | Intervention Type: DEVICE; Name: Text Message; Assigned to Arm(s): PACE | Intervention Type: BEHAVIORAL; Name: Diet Goals via Cell Phone; Assigned to Arm(s): PACE | Intervention Type: BEHAVIORAL; Name: Food Monitoring; Assigned to Arm(s): PACE
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Weight Loss Program | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Stepped-Care Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Standard Behavioral Weight Loss Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Stepped-Care Weight Loss Program; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Caregiver Psychoeducation and Support: Improving Outcomes in AD/ADRD
Brief Summary: This study is piloting an internet-based intervention to provide support for caregivers of VA patients with Alzheimer's disease or related memory difficulties (ADRD). Veterans with a clinical diagnosis of ADRD and their caregiver/relatives will be randomized to receive one of two interventions: (1) customary care (cc) and access to an intensive, interactive online education and support website intervention for 6 months, or (2) cc and monthly brief telephone calls with project staff for six month. It is hypothesized that participation in the intensive intervention will result in a reductions in patient problematic behavior and caregiver responses to it, reduced caregiver burden and depression, and improved medication adherence at the end of treatment, and more patients remaining at home through the 12 months post-randomization period..


Options:
A: Arm Label: BHL COTP Caregivers; Type: N/A; Interventions: Behavioral: BHL COTP | Intervention Type: BEHAVIORAL; Name: BHL COTP; Assigned to Arm(s): BHL COTP Caregivers
B: Arm Label: Behavioral Skills Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Skills Training: Experimental | Arm Label: Basic Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Education | Intervention Type: BEHAVIORAL; Name: Basic Education; Assigned to Arm(s): Basic Education | Intervention Type: BEHAVIORAL; Name: Behavioral Skills Training: Experimental; Assigned to Arm(s): Behavioral Skills Training
C: Arm Label: caregiver website support; Type: EXPERIMENTAL; Interventions: Behavioral: caregiver website support | Arm Label: caregiver brief supportive phone calls; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: caregiver brief supportive phone calls | Intervention Type: BEHAVIORAL; Name: caregiver website support; Assigned to Arm(s): caregiver website support | Intervention Type: BEHAVIORAL; Name: caregiver brief supportive phone calls; Assigned to Arm(s): caregiver brief supportive phone calls
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: light support, Other: 3 preventive home visits by a nurse | Arm Label: UP Protocol; Type: EXPERIMENTAL; Interventions: Other: Case Manager, Other: 3 preventive home visits by a nurse | Arm Label: UP-TECH Protocol; Type: EXPERIMENTAL; Interventions: Other: Case Manager, Other: Assistive Technologies, Other: 3 preventive home visits by a nurse | Intervention Type: OTHER; Name: Case Manager; Assigned to Arm(s): UP Protocol, UP-TECH Protocol | Intervention Type: OTHER; Name: Assistive Technologies; Assigned to Arm(s): UP-TECH Protocol | Intervention Type: OTHER; Name: light support; Assigned to Arm(s): Usual Care | Intervention Type: OTHER; Name: 3 preventive home visits by a nurse; Assigned to Arm(s): UP Protocol, UP-TECH Protocol, Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Nasally Delivered Pulmozyme in the Treatment of Sinusitis in Cystic Fibrosis Patients: A Pilot Study
Brief Summary: Chronic sinusitis is a frequent complication in cystic fibrosis. The aim of this study is to determine whether Pulmozyme(dornase alfa) would maintain sinus health (compared to placebo) in patients with cystic fibrosis who have recently undergone sinus surgery.


Options:
A: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
B: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A
C: Arm Label: Pulmozyme; Type: EXPERIMENTAL; Interventions: Drug: Pulmozyme (dornase alfa) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pulmozyme (dornase alfa); Assigned to Arm(s): Pulmozyme | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1/Phase 2, Single-Center, Controlled Study of the Effectiveness of Combined High Frequency Oscillation and Tracheal Gas Insufflation in Improving the Clinical Course of Patients With Severe Acute Respiratory Distress Syndrome
Brief Summary: In the past five years, there is a growing body of published evidence on the feasibility, and oxygenation and lung protection benefits of high frequency oscillation (HFO) in the acute respiratory distress syndrome (ARDS). The investigators have recently demonstrated the short term feasibility and additional benefits with respect to oxygenation of HFO combined with tracheal gas insufflation (TGI). In the present clinical trial, the investigators intend to test the hypothesis that HFO-TGI may result in improved respiratory physiology and clinical course compared to low tidal volume conventional mechanical ventilation in patients with severe ARDS.


Options:
A: Arm Label: HFO-TGI; Type: EXPERIMENTAL; Interventions: Other: High Frequency Oscillation and Tracheal Gas Insufflation | Arm Label: CMV; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: High Frequency Oscillation and Tracheal Gas Insufflation; Assigned to Arm(s): HFO-TGI
B: Intervention Type: DEVICE; Name: High-frequency oscillation; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Conventional lung-open mechanical ventilation; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: prone position | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone position; Assigned to Arm(s): A

Answer: A